【佳學(xué)基因檢測(cè)】成人I型神經(jīng)纖維瘤病患者診斷與護(hù)理 (ACMG)

腫瘤基因檢測(cè)有用嗎分析

分析腫瘤分子診斷與基因分析了解《Genet Med》在?2018 Jul;20(7):671-682發(fā)表了一篇題目為《成人I型神經(jīng)纖維瘤病患者診斷與護(hù)理 (ACMG)》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Douglas R Stewart,?Bruce R Korf,?Katherine L Nathanson?,?David A Stevenson,?Kaleb Yohay?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

I型,神經(jīng)纖維瘤,資源,共識(shí),數(shù)據(jù)

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

神經(jīng)纖維瘤實(shí)踐資源是為醫(yī)學(xué)遺傳學(xué)家和其他臨床醫(yī)生的教育學(xué)習(xí)資源，以幫助他們提供優(yōu)質(zhì)的醫(yī)療服務(wù)。使用此實(shí)踐資源有效是自愿的，資源編撰方并不一定能高效成功的醫(yī)療結(jié)果。該實(shí)踐資源不應(yīng)被視為包括所有適當(dāng)?shù)脑\斷治療方案和測(cè)試，或不包括合理地用于獲得相同結(jié)果的其他方案和檢測(cè)。在確定任何特定程序或測(cè)試的適當(dāng)性時(shí)，臨床醫(yī)生應(yīng)將他或她自己的專業(yè)判斷應(yīng)用于個(gè)體患者或樣本所呈現(xiàn)的特定臨床情況。鼓勵(lì)臨床醫(yī)生記錄使用特定程序或測(cè)試的原因，無(wú)論它是否符合本實(shí)踐資源。還建議臨床醫(yī)生注意該實(shí)踐資源的采用日期，并考慮在該日期之后可用的其他醫(yī)學(xué)和科學(xué)信息。謹(jǐn)慎考慮知識(shí)產(chǎn)權(quán)是否可能會(huì)限制某些測(cè)試和其他程序的執(zhí)行。1型神經(jīng)纖維瘤基因檢測(cè)及個(gè)性化診斷治療的目的：1 型神經(jīng)纖維瘤病 (NF1) 是一種常染色體顯性遺傳疾病，由腫瘤抑制基因NF1雜合功能喪失突變引起。根據(jù)佳學(xué)基因《腫瘤大數(shù)據(jù)庫(kù)及人工智能分析》，I型神經(jīng)纖維瘤的發(fā)生率在全球范圍內(nèi)約為 1/1,900-1/3,500 人。這種疾病使得男性和女性的平均預(yù)期壽命減少 8-15 年，主要是因?yàn)閻盒阅[瘤和心血管的發(fā)生。1型神經(jīng)纖維瘤的基因解碼方法：基因解碼團(tuán)隊(duì)先組建一個(gè)專家工作組試圖確定患病率、發(fā)病率和死亡率，以及可用的治療成人常見(jiàn)和新出現(xiàn)的 NF1 相關(guān)臨床疾病。工作組成員選擇經(jīng)過(guò)同行評(píng)議的包括發(fā)表在 PubMed 的研究數(shù)據(jù)。對(duì)大人群研究和多機(jī)構(gòu)參與研究獲得的數(shù)據(jù)給與更高的權(quán)重和優(yōu)先性。神經(jīng)纖維瘤基因解碼基因檢測(cè)所采納的治療和護(hù)理 建議是由從這些研究數(shù)據(jù)中及歸納專業(yè)人員所形成的共識(shí)。I型神經(jīng)纖維瘤基因解碼基因檢測(cè)分析研究結(jié)果：惡性外周神經(jīng)鞘瘤 (MPNST)、乳腺癌、皮膚神經(jīng)纖維瘤以及重要的精神和神經(jīng)系統(tǒng)病是 NF1 患者的常見(jiàn)臨床表現(xiàn)出現(xiàn)的地方。I型神經(jīng)纖維瘤基因解碼分析結(jié)論：患者教育和對(duì)令人擔(dān)憂的體征和癥狀（如進(jìn)行性劇烈疼痛（MPNST）、腫瘤體積變化（MPNST）、新的、無(wú)法解釋的神經(jīng)系統(tǒng)癥狀（MPNST、腦腫瘤）和出汗/心悸（嗜鉻細(xì)胞瘤））的敏感性很重要。盡管 NF1 成人患者的許多問(wèn)題可以由內(nèi)科醫(yī)生或家庭醫(yī)生處理，但I(xiàn)型神經(jīng)纖維瘤強(qiáng)烈建議由專門的 NF1 診所進(jìn)行評(píng)估和護(hù)理協(xié)調(diào)。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Disclaimer:?This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessarily assure a successful medical outcome. This practice resource should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinician should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure or test, whether or not it is in conformance with this practice resource. Clinicians also are advised to take notice of the date this practice resource was adopted, and to consider other medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.Purpose:?Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that is caused by a heterozygous loss-of-function variant in the tumor suppressor gene NF1; it affects ~1/1,900-1/3,500 people worldwide. The disorder is associated with an 8-15-year reduction in average life expectancy in both men and women, primarily due to malignant neoplasms and cardiovascular causes.Methods:?A work group of experts sought to determine the prevalence, morbidity and mortality, and available treatments of common and emerging NF1-related clinical problems in adults. Work-group members identified peer-reviewed publications from PubMed. Publications derived from populations and multi-institution cohorts were prioritized. Recommendations for management arose by consensus from this literature and the collective expertise of the authors.Results:?Malignant peripheral nerve sheath tumor (MPNST), breast cancer, cutaneous neurofibromas, and significant psychiatric and neurologic diagnoses are common problems in patients with NF1.Conclusion:?Patient education and sensitization to worrisome signs and symptoms such as progressive severe pain (MPNST), changes in tumor volume (MPNST), new, unexplained neurologic symptoms (MPNST, brain tumors), and diaphoresis/palpitations (pheochromocytoma) are important. Although many issues in adults with NF1 can be managed by an internist or family physician, we strongly encourage evaluation by, and care coordination with, a specialized NF1 clinic.